Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Pemetrexed; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dry Eye Syndrome
Interventions: RX-10045, Vehicle for RX-10045; Drug
Lead sponsor: C.T. Development America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Osteo Arthritis Shoulders, Avascular Necrosis of the Head of Humerus, Rotator Cuff Tear
Interventions: Easytech group; Device
Lead sponsor: FX Shoulder Solutions; Industry
Eligibility: 21 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 6
States / cities: Sun City West, Arizona • Menlo Park, California • Philadelphia, Pennsylvania + 3 more

Conditions: Heart Failure, Cardiomyopathies
Interventions: EXCOR Pediatric; Device
Lead sponsor: Berlin Heart, Inc; Industry
Eligibility: 1 Day to 16 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 12 more

Conditions: Urinary Incontinence, Urge
Interventions: StimGuard Sacral Nerve Stimulator System; Device
Lead sponsor: Uro Medical Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Medulloblastoma
Interventions: LDE225, TMZ; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 4 Months and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Schizophrenia
Interventions: Placebo, Bitopertin, Antipsychotics; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 27
States / cities: Costa Mesa, California • Escondido, California • Granada Hills, California + 24 more

Conditions: Parkinson Disease, Stroke, Multiple Sclerosis, Gait Disorders, Neurologic, Gait Disorder, Sensorimotor, Gait, Unsteady, Gait Ataxia, Gait, Stumbling, Gait, Shuffling
Interventions: Feedback-assisted physical therapy, Traditional physical therapy; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 60 Years to 89 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Salem, Oregon

Conditions: Hepatitis C, Chronic
Interventions: Previous treatment in DEB025 study; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: San Diego, California • Ventura, California • Honolulu, Hawaii + 4 more

Conditions: Open Angle Glaucoma
Interventions: Travoprost; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 13
States / cities: Hemet, California • Petaluma, California • Fort Collins, Colorado + 10 more

Conditions: Chronic Myelogenous Leukemia - Chronic Phase
Interventions: ABL001; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 26
States / cities: Anchorage, Alaska • Phoenix, Arizona • Long Beach, California + 21 more

Conditions: Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
Interventions: NRP104; Drug
Lead sponsor: New River Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 48
States / cities: Little Rock, Arkansas • El Centro, California • Irvine, California + 43 more

Conditions: Breast Neoplasms, Breast Cancer, Metastasis
Interventions: CAL; Drug
Lead sponsor: Chugai Pharma USA; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 38
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Concord, California + 32 more

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 31
States / cities: Birmingham, Alabama • Aurora, California • Fresno, California + 28 more

Conditions: Healthy
Interventions: Warfarin; Dantonic; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: MPS-IH (Hurler Syndrome)
Interventions: Experimental: OTL-203, Active Comparator: Allo-HSCT; Genetic
Lead sponsor: Orchard Therapeutics; Industry
Eligibility: 28 Days to 30 Months
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Primary Ciliary Dyskinesia, Healthy
Interventions: Lung Function Testing, Phlebotomy, Allergy skin prick testing, Methacholine Challenge; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 6 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Idiopathic Short Stature
Interventions: Genotropin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Years to 10 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 43
States / cities: Little Rock, Alaska • Little Rock, Arkansas • Los Angeles, California + 32 more

Conditions: Coronary Artery Disease
Interventions: CT angiography, Invasive coronary angiography; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 45 Years to 85 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Interventions: LY4405094, Placebo, Florbetapir F18, Florbetaben F 18; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Anaheim, California • Irvine, California • Los Alamitos, California + 10 more

Conditions: Healthy
Interventions: Dexamethasone Ophthalmic, Dilator; Drug · Device
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, ORMD-0801 QD, ORMD-0801 BD; Other · Drug
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Tustin, California

Conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Interventions: AUTO1; Biological
Lead sponsor: Autolus Limited; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 23
States / cities: Duarte, California • La Jolla, California • Sacramento, California + 20 more

Conditions: Urolithiasis
Interventions: Storz single Lumen Ureteroscope, Dual Lumen Ureteroscope; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Orange, California

Search by objective public record fields.

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

A Study of RX-10045 in the Treatment of Dry Eye Disease

Easytech Reversed Shoulder System Clinical Study

Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device

Sacral Nerve Stimulation to Treat Urgency Urinary Incontinence With Wireless Neuromodulation

A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

Mobility Rehab, a Therapist-assisted System for Gait Rehabilitation

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study

Study of Exchange of Travoprost Intraocular Implant

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer

Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

A Study to Evaluate the Effect of T89(Dantonic®)on Steady-State Pharmacodynamics of Warfarin

A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

Ultra-high-resolution CT vs. Conventional Angiography for Detecting Coronary Heart Disease

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects

Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Multi-Center Comparison of Dual Lumen Versus Single Lumen Ureteroscopes